Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.

Danish drugmaker Novo Nordisk (NVO) reported fourth quarter ... Novo is working on building new manufacturing sites to combat this, and the closing of the Catalent deal at the end of 2024 that ...